Newsfeeds - Spark Newswire

2 minute read

News

Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma

Today, 5:32 AM

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and SpringWorks

DTIL

1 minute read

SpringWorks Therapeutics Reveals Updated Interim Mirdametinib Data In Rare Genetic Disorder

By Vandana Singh

Today, 5:32 AM

SpringWorks Therapeutics Inc (NASDAQ:SWTX) announced an update on the previously reported interim data from the first 20 adult patients enrolled in…

SWTX

1 minute read

SpringWorks Therapeutics Announces Initiation Of Phase 1/2 Clinical Trial Of Mirdametinib In Children And Young Adults With Low-Grade Glioma

By Bill Haddad

Today, 5:32 AM

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported the initiation of a

SWTX

3 minute read

News

SpringWorks Therapeutics Highlights Presentation Of Updated Data From Phase 2b ReNeu Trial At Children’s Tumor Foundation Conference

By Benzinga Newsdesk

Today, 5:32 AM

Additional Follow-up of First 20 Adult Patients Enrolled Continues to Show Encouraging Efficacy and Tolerability of Mirdametinib in Patients with NF1-PN STAMFORD, Conn., June 15, 2021 (GLOBE NEWSWIRE) -- SpringWorks

SWTX

Latest news

Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma

SpringWorks Therapeutics Reveals Updated Interim Mirdametinib Data In Rare Genetic Disorder

SpringWorks Therapeutics Announces Initiation Of Phase 1/2 Clinical Trial Of Mirdametinib In Children And Young Adults With Low-Grade Glioma

SpringWorks Therapeutics Highlights Presentation Of Updated Data From Phase 2b ReNeu Trial At Children’s Tumor Foundation Conference